Serotonergic activity in the rat striatum after intrastriatal transplantation of fetal nigra as measured by microdialysis. 1998

Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
Department of Psychiatry, Miyazaki Medical College, 5200 Kihara, Kiyotake-cho, Miyazaki-gun, Miyazaki 889-16, Japan. ishiday@post.miyazaki-med.ac.jp

In vivo microdialysis was used to examine the effects of dopaminergic transplants on extracellular concentrations of dopamine (DA), serotonin (5-HT), and their precursors and major metabolites in the denervated rat striatum. Dialysis perfusates were collected from intact 6-hydroxydopamine (6-OHDA) lesion plus sham grafted, and lesion plus fetal substantia nigra (SN) grafted striata. The SN transplants ameliorated the reduction of striatal DA and dihydroxyphenylacetic acid (DOPAC) levels in rats with unilateral 6-OHDA lesions of the mesostriatal pathway. The transplants also increased extracellular levels of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) in the denervated striatum. In response to NSD-1015 (an inhibitor of aromatic L-amino acid decarboxylase, AADC), 5-hydroxytryptophan (5-HTP) levels were substantially elevated in the SN grafted striata as compared with those in the sham grafted controls, which continued even after subsequent administration of L-3,4-dihydroxyphenylalanine (L-DOPA, 100 mg/kg i.p.). Immunohistochemical analysis showed hyperinnervation of 5-HT fibers in the grafted striatum, which was consistent with the results of microdialysis experiments. These results indicated that implantation of SN grafts into the 6-OHDA-lesioned striatum of rats induces hyperactivity of 5-HT synthesis, release and metabolism.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D006897 Hydroxyindoleacetic Acid 5-HIAA,5-Hydroxy-3-Indoleacetic Acid,5-Hydroxyindolamine Acetic Acid,5 Hydroxy 3 Indoleacetic Acid,5 Hydroxyindolamine Acetic Acid,Acetic Acid, 5-Hydroxyindolamine,Acid, 5-Hydroxy-3-Indoleacetic,Acid, 5-Hydroxyindolamine Acetic,Acid, Hydroxyindoleacetic
D006916 5-Hydroxytryptophan The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant. 5-HTP,Hydroxytryptophan,Oxitriptan,Oxytryptophan,Tryptophan, 5-Hydroxy-,5 Hydroxytryptophan,5-Hydroxy- Tryptophan,Tryptophan, 5 Hydroxy
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras

Related Publications

Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
June 1991, Brain research,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
January 1990, Brain research,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
April 1999, Canadian journal of physiology and pharmacology,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
December 2004, Amino acids,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
March 1995, The Journal of pharmacology and experimental therapeutics,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
April 1996, Neuroscience letters,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
May 1992, Journal of neurochemistry,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
July 1990, Brain research bulletin,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
March 1997, Neurochemistry international,
Y Ishida, and H Hashiguchi, and K Todaka, and I Kuwahara, and Y Ishizuka, and H Nakane, and D Uchimura, and T Nishimori, and Y Mitsuyama
June 1993, Experimental neurology,
Copied contents to your clipboard!